bio techne nbp1 51641 goat igg anti human sox2 if  (Bio-Techne corporation)

Journal: Journal of respiratory biology and translational medicine

Article Title: Mitochondrial Lon Peptidase 1 Controls Diaphragm and Lung Development in a Context-Dependent Manner

doi: 10.70322/jrbtm.2025.10008

Figure Lengend Snippet: ( A – C ) Representative images of SOX2 and SOX9 staining in the lungs of Shhcre;Lonp1 and control mice at E13.5. Scale bars, 200 μm. Quantifications of SOX2 ( B ) and SOX9 ( C ) were shown, respectively. ( D , E ) In situ hybridization analysis of Sox2 ( D ) and Sox9 ( E ) RNAs in the lungs of Shhcre;Lonp1 and control mice at E12.5. Scale bars, 200 μm. Selected airway regions were boxed and magnified on the top right. ( F , G ) Representative images of aSMA staining in the lungs of Shhcre;Lonp1, and control mice at E13.5 ( F ). Selected airway regions were boxed and magnified on the right: scale bars, 200 μm. Quantifications were shown in ( G ).

Article Snippet: Primary antibodies with final concentrations used for immunofluorescence staining are: rabbit anti-SOX2 polyclonal antibody [8 mg/mL] (NB110–37235, Novus Biologicals, Centennial, CO, USA), mouse anti-SOX9 monoclonal antibody [5 mg/mL] (AMAB90795, Sigma, Tokyo, Japan), mouse anti-aSMA monoclonal antibody [5 mg/mL] (A2547, Sigma), mouse anti-E-cadherin monoclonal antibody [8 mg/mL] (610181, BD Transduction Laboratories, NJ, USA), rabbit anti-E-cadherin polyclonal antibody [5 mg/mL] (3195, Cell Signaling Technology, Danvers, MA, USA), rabbit anti-FOXA1 monoclonal antibody [5 mg/mL] (ab173287, Abcam, Cambridge, UK) and rabbit anti-FOXA2 monoclonal antibody [5 mg/mL] (ab108422, Abcam).

Techniques: Staining, Control, In Situ Hybridization

Journal: iScience

Article Title: WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5/C-X-C chemokine receptor type 2/leukemia inhibitory factor/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer.

doi: 10.1016/j.isci.2024.110562

Figure Lengend Snippet: Figure 3. Knockdown of WPMY-1 suppresses LIF-driven neuroendocrine differentiation (NED) and malignant progression in prostate cancer (PCa) cells (A) Relative protein levels of LIF, LIFR, WISP1, SOCS3, and PDL1 were measured in AR-positive PCa cell lines (LNCaP, C4-2, and 22Rv1), an AR-negative PCa cell line (PC3), and an NEPC cell line (LASCPC-01). (B) Relative protein levels of WISP1, phosphorylated (p)-STAT3, STAT3, PDL1, and SOCS3 were measured in LNCaP cells treated with PBS or 100 ng/mL of the LIF recombinant protein for a duration ranging 0 to 96 h. (C) Relative mRNA levels of WISP1, neuroendocrine (CHGA, SYP, and ENO2), stem cell (SOX2 and NANOG), and anti-inflammatory (SOCS3 and PDL1) markers in LNCaP cells treated with PBS or 100 ng/mL of the LIF recombinant protein or combined treatment with DMSO or 35 nM EC330 for 48 h * vs. PBS+DMSO; # vs. LIF+DMSO, as determined by a one-way ANOVA. (D) Relative protein levels of WISP1, p-STAT3, STAT3, PDL1, and SOCS3 in LNCaP and C4-2 cells cultured in PBS or 100 ng/mL of the LIF recombinant protein, followed by DMSO or 35 nM EC330 treatment for 48 h. (E) Relative mRNA expression levels of WISP1, neuroendocrine markers, stem cell markers, and anti-inflammatory markers (SOCS3 and PDL1) were measured in LNCaP cells expressing the non-target control (NC) or WISP1 siRNA, followed by treatment with PBS or 100 ng/mL of the LIF recombinant protein for 48 h * vs. PBS+NC; # vs. LIF+NC, as determined by a one-way ANOVA. (F and G) Relative cell proliferation (F) and sphere formation (G) were measured in LNCaP cells expressing either NC or WISP1 siRNA, followed by treatment with either PBS or 100 ng/mL of LIF recombinant protein for 5 days (F) or 1 week (G). Scale bars represent 100 mm (G). * vs. PBS+NC; # vs. LIF+NC, as determined by a one-way ANOVA. (H and I) Relative cell migration (H) and invasion through Matrigel (I) were measured in LNCaP cells expressing the NC or WISP1 siRNA, followed by treatment with PBS or 100 ng/mL of LIF recombinant protein for 12 h. Scale bars representing 20 mm are shown. * vs. PBS+NC; # vs. LIF+NC, as determined by a one-way ANOVA. Quantification of relative mRNA levels, cell proliferation, sphere formation, and cell invasion through Matrigel is presented as the mean G SEM from three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.005. (J) A GSEA of the TCGA PCa dataset revealed significant associations between high WISP1 expression in prostate tissues and a gene signature representing NEPC-responsive signaling. NES, normalized enrichment score; FDR, false discovery rate.

Article Snippet: Antibodies CXCL5 ThermoFisher 710010 CXCR2 Abcam ab217314 CHGA Cell signaling Cat#85798 SOX2 NOVUS NB110-37235 LIF Cloud PAA085Hu01 p-STAT3 Cell signaling Cat#9145 LIFR Proteintech 22779-1-AP STAT3 Cell signaling Cat#9139 PDL1 Proteintech 66248-1-Ig WISP1 ThermoFisher PA5-106451 ENO2 Abcam ab218388 b-actin Merck MAB1501

Techniques: Knockdown, Recombinant, Cell Culture, Expressing, Control, Migration

Journal: iScience

Article Title: WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5/C-X-C chemokine receptor type 2/leukemia inhibitory factor/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer.

doi: 10.1016/j.isci.2024.110562

Figure Lengend Snippet: Figure 4. Crosstalk between prostate cancer (PCa) cells and prostate stromal cells promotes neuroendocrine differentiation (NED) and expressions of immunosuppressive cytokines in the tumor microenvironment (TME) through the activation of LIF/LIFR signaling (A) Relative mRNA expression levels of WISP1, neuroendocrine markers (CHGA, SYP, and ENO2), stem cell markers (SOX2 and NANOG), anti-inflammatory markers (SOCS3 and PDL1), LIF, CXCR2, and CXCL5 in LNCaP cells. These cells were cultured with conditioned medium (CM) collected from human WPMY-1 stromal cells, at concentrations of 0%, 15%, or 50%, for a duration of 48 h * vs. 0%, as determined by a one-way ANOVA. (B) Relative mRNA expression levels of WISP1, neuroendocrine markers, stem cell markers, anti-inflammatory markers, LIF, CXCR2, and CXCL5 were measured in LNCaP cells. These cells were cultured with CM obtained from WPMY-1 stromal cells treated with DMSO or 35 nM EC330 for 48 h * vs. Veh+DMSO; # vs. WPMY-1 CM + DMSO, as determined by a one-way ANOVA. (C) Relative mRNA expression levels of WISP1, neuroendocrine, stem cell, anti-inflammatory markers, LIF, CXCR2, and CXCL5 in LNCaP cells cultured with CM collected from the non-target control (Luc) or LIFR shRNA-expressing WPMY-1 cells for 48 h * vs. Veh; # vs. WPMY-1/shLuc CM, as determined by a one-way ANOVA. (D) Relative mRNA expression levels of LIFR, LIF, CXCL5, WISP1, and anti-inflammatory markers (IL10, IL4, IL1RN, TGFB1, VEGFA, IFNA17, and SOCS3) in WPMY-1 cells stably expressing the shLuc or LIFR shRNA. * vs. shLuc, as determined by a one-way ANOVA. (E) Relative mRNA expression levels of LIFR, LIF, CXCL5, WISP1, and anti-inflammatory markers in WPMY-1 cells treated with PBS or 100 ng/mL of the LIF recombinant protein, followed by DMSO or 35 nM EC330 treatment for 48 h * vs. PBS+DMSO; # vs. LIF+DMSO, as determined by a one-way ANOVA. (F and G) Cell proliferation (F) and sphere formation (G) of LNCaP cells were evaluated. These cells were cultured with CM obtained from WPMY-1 stromal cells treated with DMOS or 35 nM EC330 for 48 h. Scale bars in (G) represent 100 mm. Statistical comparisons were performed using a one-way ANOVA. * vs. Veh+DMSO; # vs. WPMY-1 CM + DMSO. (H and I) Relative cell migration (H) and invasion through Matrigel (I) were measured in LNCaP cells. These cells were cultured with CM obtained from WPMY-1 stromal cells treated with DMSO or 35 nM EC330 for 12 h. Scale bars representing 20 mm are shown. * vs. Veh+DMSO; # vs. WPMY-1 CM + DMSO, as determined by a one-way ANOVA. Quantification of relative mRNA levels, cell proliferation, sphere formation, and cell invasion through Matrigel is presented as the mean G SEM, based on three biological replicates. Significance levels are denoted as *p < 0.05, **p < 0.01, and ***p < 0.005.

Article Snippet: Antibodies CXCL5 ThermoFisher 710010 CXCR2 Abcam ab217314 CHGA Cell signaling Cat#85798 SOX2 NOVUS NB110-37235 LIF Cloud PAA085Hu01 p-STAT3 Cell signaling Cat#9145 LIFR Proteintech 22779-1-AP STAT3 Cell signaling Cat#9139 PDL1 Proteintech 66248-1-Ig WISP1 ThermoFisher PA5-106451 ENO2 Abcam ab218388 b-actin Merck MAB1501

Techniques: Activation Assay, Expressing, Cell Culture, Control, shRNA, Stable Transfection, Recombinant, Migration

Journal: iScience

Article Title: WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5/C-X-C chemokine receptor type 2/leukemia inhibitory factor/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer.

doi: 10.1016/j.isci.2024.110562

Figure Lengend Snippet: Figure 6. WISP1 abundance in serum relative to prostate cancer (PCa) progression (A) Relative mRNA levels of CXCL5, CXCR2, LIF, WISP1, neuroendocrine (CHGA, SYP, and ENO2), and stem cell (SOX2 and NANOG) markers in C4-2 cells expressing the empty vector (EV) or CXCL5-expressing vector, followed by treatment with DMSO or 35 nM EC330 for 48 h * vs. EV + DMSO; # vs. CXCL5+DMSO, as determined by a one-way ANOVA. (B and C) Tumor growth analysis was conducted by subcutaneously inoculating male nude mice with C4-2 cells expressing either the EV or a CXCL5-expressing vector. The mice were then treated bi-daily with either DMSO or 2.5 mg/kg EC330 via intraperitoneal injection and allowed to grow for 8 weeks. Tumor sizes were measured weekly (B). Tumor weights were measured upon tumor collection (C). n = 5 per group. * vs. EV + DMSO; # vs. CXCL5+DMSO, as determined by a one- way ANOVA and t-test. (D and E) Immunohistochemical (IHC) staining and intensity analyses were performed to assess protein levels of CXCL5, CXCR2, LIF, WISP1, and ENO2 in subcutaneous tumors derived from (B). * vs. EV + DMSO; # vs. CXCL5+DMSO, as determined by a two-tailed Student’s t-test. Scale bars, 100 mm. (F) WISP1 concentrations were measured in patient sera derived from samples of benign prostatic hyperplasia (BPH; n = 10), hormone-sensitive PCa (HSPC, n = 10), and metastatic castration-resistant PCa (mCRPC; n = 8). * vs. BPH; # vs. HSPC, analyzed by a one-way ANOVA.

Article Snippet: Antibodies CXCL5 ThermoFisher 710010 CXCR2 Abcam ab217314 CHGA Cell signaling Cat#85798 SOX2 NOVUS NB110-37235 LIF Cloud PAA085Hu01 p-STAT3 Cell signaling Cat#9145 LIFR Proteintech 22779-1-AP STAT3 Cell signaling Cat#9139 PDL1 Proteintech 66248-1-Ig WISP1 ThermoFisher PA5-106451 ENO2 Abcam ab218388 b-actin Merck MAB1501

Techniques: Expressing, Plasmid Preparation, Injection, Immunohistochemical staining, Immunohistochemistry, Derivative Assay, Two Tailed Test

Journal: iScience

Article Title: N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer

doi: 10.1016/j.isci.2024.108956

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti-SOX2 , Novus , Cat#NB110-79875; RRID: AB_1110593.

Techniques: Recombinant, Software

Journal: iScience

Article Title: N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer

doi: 10.1016/j.isci.2024.108956

Figure Lengend Snippet:

Article Snippet: The primary antibodies used were anti-B7-H3 (1:400; Proteintech, Cat No. 14453-1-AP), anti-ALDH (1:100; Abcepta, Cat No. AP1465c), anti-CD133 (1:500; Abcam, Cat No. ab27699), anti-MYC (1:500; Abcam, Cat No. ab18185), anti-NANOG (1:500; Novus, Cat No. NB100-58842), anti-SOX2 (1:300; Novus, Cat No. NB110-79875), anti-Ki67 (1:200; Proteintech, Cat No. 27309-1-AP), anti-Slug (1:1000; OriGene, Cat No. TA800167), anti-N-cadherin (1:5000; Proteintech, Cat No. 22018-1-AP) and anti-E-cadherin (1:2000; OriGene, Cat No. TA800692).

Techniques: Recombinant, Software

Journal: iScience

Article Title: N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer

doi: 10.1016/j.isci.2024.108956

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti-SOX2 , Novus , CatNB110-79875; RRID: AB_1110593.

Techniques: Recombinant, Software

Journal: Cells

Article Title: Rat Plantar Fascia Stem/Progenitor Cells Showed Lower Expression of Ligament Markers and Higher Pro-Inflammatory Cytokines after Intensive Mechanical Loading or Interleukin-1β Treatment In Vitro.

doi: 10.3390/cells12182222

Figure Lengend Snippet: Figure 5. Expression of stemness markers in PFCs compared to BMSCs. (A) Photomicrographs showing the immunocytochemical staining of Nanog, Oct4, Sox2, and nucleostemin (NS) (upper left: primary antibody, lower left: DAPI, right: merged). Magnification: 200×; scale bar: 100 µm; n = 3/group. (B) Bar charts showing the mRNA expression of Nanog, Oct4, and Sox2 in PFCs and BMSCs. *** p < 0.001; n = 6/group.

Article Snippet: The cells were then washed with PBS, fixed in 4% paraformaldehyde for 15 min, permeabilized with 0.25% Triton X-100 for 10 min, and blocked with 5% normal goat serum for 1 h. Afterwards, the cells were incubated with mouse anti-rat Ki67 (ab279653), rabbit anti-rat Nucleostemin (NS) (ab70346) (both from Abcam, Cambridge, UK), rabbit anti-rat Nanog (NBP1-77109), Oct4 (NB100-2379SS) or Sox2 (NB110-37235SS) (all from Novus Biologicals, Centennial, CO, USA) (1:200 all) overnight at 4 ◦C.

Techniques: Expressing, Staining

Journal: Neural Regeneration Research

Article Title: Necroptosis plays a crucial role in the exacerbation of retinal injury after blunt ocular trauma

doi: 10.4103/1673-5374.353848

Figure Lengend Snippet: Müller cell regeneration and gliosis occur after blunt ocular trauma. (A) Representative images of Ki67 (green) and GS (red) staining. After blunt ocular trauma, the number of Ki67/GS double-positive cells increased over time and reached a peak on the third day. (B) The number of Ki67/GS double-positive cells was recorded. (C) Representative images of SOX2 (green) and GS (red) staining. The number of SOX2/GS double-positive cells increased over time after blunt ocular trauma. (D) The number of SOX2/GS double-positive cells was recorded. (E) Representative images of GFAP (green) staining. The number of GFAP-positive cells increased on the seventh day after blunt ocular trauma. Scale bar: 50 μm. (F) The number of GFAP-positive cells was recorded. Data are shown as the mean ± SEM ( n = 5 per group). * P < 0.05, vs . control group (Student’s t -test). GCL: Ganglion cell layer; GFAP: glial fibrillary acidic protein; GS: glutamine synthetase; INL: inner nuclear layer; ONL: outer nuclear layer; SOX2: SRY-box transcription factor 2.

Article Snippet: Sections were then incubated at 4°C overnight with one or more of the following primary antibodies [all diluted 1:100 by a fresh blocking buffer (0.01 M PBS containing 0.3% Triton X-100 and 3% bovine serum albumin)]: synaptophysin (Syn; rabbit; Aviva Systems Biology, San Diego, CA, USA; Cat# ARP45435, RRID: AB_2048301), Ki67 (rabbit; Proteintech, Wuhan, China; Cat# 27309-1-AP, RRID: AB_2756525), glutamine synthetase (GS; mouse; Proteintech; Cat# 66323-2-Ig, RRID: AB_2881704), CD45 (rabbit; Proteintech; Cat# 20103-1-AP, RRID: AB_2716813), sex determining region Y-box 2 (SOX2) (rabbit; Novus, Littleton, CO, USA; Cat# NB110-37235, RRID: AB_792070), protein kinase C (PKC; mouse; Enzo, New York, NY, USA; Cat# ADI-KAM-PK020, RRID: AB_10998587), inducible nitric oxide synthase 2 (iNOS) (mouse; Santa Cruz Biotechnology, Dallas, TX, USA; Cat# sc-7271, RRID: AB_2891105), glial fibrillary acidic protein (GFAP; mouse; Millipore, Burlington, MA, USA; Cat# MAB3402, RRID: AB_94844), calretinin (rabbit; Abcam, Cambridge, UK; Cat# ab702, RRID: AB_305702), choline acetyltransferase (ChAT; rabbit; Abcam; Cat# ab6168, RRID: AB_2244866), ionized calcium binding adapter molecule 1 (Iba1) (rabbit; Abcam; Cat# ab178847, RRID: AB_2832244), Iba1 (mouse; Abcam; Cat# ab15690, RRID: AB_2224403), calbindin-D (rabbit; Sigma, St. Louis, MO, USA; Cat# c2724, RRID: AB_258818), or CD16/32 (rabbit; Abcam; Cat# ab223200).

Techniques: Staining, Control